### FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

# Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

						360		(ii) of the	mvestine	iii Cu	прапу Аст	01 1940									
Name and Address of Reporting Person*     Cartt Stephen LaHue						2. Issuer Name and Ticker or Trading Symbol QUESTCOR PHARMACEUTICALS INC QCOR ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner						
(Last) 1300 NC	•	irst) LOGG DRIVE	(Middle) DRIVE				3. Date of Earliest Transaction (Month/Day/Year) 08/14/2014									X Officer (give title Other (specify below)  Chief Operating Officer					
(Street) ANAHE	Street) ANAHEIM CA 92807					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	State)	(Zip)	. Davis		6		4: 4-		D:-			4								
Table I - Non-Deriv  1. Title of Security (Instr. 3)  2. Trans Date (Month/					sactio	n	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Trans	3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount		A) or D)	Price	Reported Transaction (Instr. 3 au				(Instr. 4)		
Common Stock 08/14						1/2014			<b>D</b> <sup>(1)</sup>		109,78	85	5 D		0		D				
Common Stock 08/14					4/20	14			D <sup>(2)</sup>		46,25	46,250 I		(2)	0		D				
Common Stock 08/3					/14/2014				D <sup>(3)</sup>		23,00	23,000		(3)	0			D			
			Table II -					-	-		osed of,			-	Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/	ate, 4.	ansaction ode (Instr.		Derivative		6. Date Exercise Expiration Date (Month/Day/Yea		sable and	of Securities		mount	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported	Ownersh Form: Direct (D or Indirect (I) (Instr.	Ownership	Beneficial Ownership t (Instr. 4)		
				Co	ode	le V (		(D)	Date Exercisa		Expiration Date	Title	or Nu	nount ımber Shares		Transacti (Instr. 4)	ion(S)				
Stock Option (right to buy)	\$5.09	08/14/2014		D	(4)(5)			30,491	(6)		02/05/2018	Comm		0,491	(4)(5)	0		D			
Stock Option (right to buy)	\$5.1	08/14/2014		D	(4)(5)			100,000	(6)		02/25/2019	Comm		00,000	(4)(5)	0		D			
Stock Option (right to buy)	\$5.12	08/14/2014		D	(4)(5)			130,000	(6)		01/18/2020	Comm		30,000	(4)(5)	0		D			

## **Explanation of Responses:**

\$14.24

\$35,78

08/14/2014

08/14/2014

 $D^{(4)(5)}$ 

D<sup>(4)(5)</sup>

Stock Option

(right to buy)

Stock Option (right to

1. Pursuant to Agreement and Plan of Merger, dated April 5, 2014 (the "Merger Agreement"), by and among Mallinckrodt plc ("Mallinckrodt"), Quincy Merger Sub, Inc. and Questcor Pharmaceuticals, Inc. ("Questcor"), Mallinckrodt acquired Questcor in a merger transaction (the "Merger") which closed at 4:30 p.m. EST, on August 14, 2014 (the "Effective Time"). At the Effective Time, each share of Questcor common stock (except for certain shares defined in the Merger Agreement) converted into the right to receive, without interest, (a) \$30.00 in cash and (b) 0.897 of an ordinary share of Mallinckrodt, in exchange for such share of Questcor common stock ("Merger Consideration").

(7)

(8)

150,000

99,375

Common

Stock

Common

Stock

150,000

99,375

(4)(5)

(4)(5)

0

0

D

D

02/15/2021

02/14/2022

- 2. Pursuant to terms of the Merger, at the Effective Time, each outstanding Questcor restricted share award (other than any such award subject to performance-based vesting conditions) held by Questcor executive officers converted into a number of restricted Mallinckrodt ordinary shares determined by multiplying the applicable number of restricted shares of Questcor common stock by the Equity Award Exchange Ratio.
- 3. Pursuant to terms of the Merger, at the Effective Time, each outstanding Questcor restricted share award held by a Questcor executive that is subject to performance-based vesting conditions was cancelled and converted into the right to receive Merger Consideration in respect of each share of Questcor common stock underlying the Questcor restricted share award.
- 4. Pursuant to terms of the Merger, at the Effective Time, each vested Questcor stock option held by Questcor executive officers converted into the right to receive the Merger Consideration with respect to each share of Company common stock subject to such option immediately prior to the effective time of the Merger, net of the applicable exercise price, while each unvested Questcor stock option held by Questcor executive officers converted into an option to acquire, on the same terms and conditions as were applicable to such option immediately prior to the Effective Time, a number of Mallinckrodt ordinary shares determined by multiplying the number of shares of Questcor common stock subject to such option immediately prior to the effective Time, a number of Mallinckrodt ordinary shares determined by multiplying the number of shares of Questcor common stock subject to such option immediately prior to the effective time of the Merger by the Equity Award Exchange Ratio,
- 5. (Continued from footnote 4) at an exercise price per share of Mallinckrodt ordinary shares (rounded up to the nearest whole cent) equal to the quotient obtained by dividing (x) the exercise price per share of Questcor common stock of such Questcor stock option by (y) the Equity Award Exchange Ratio.
- 7. The stock option is exercisable as it vests 25% of the shares subject to the stock option vest on the first anniversary of the grant date, while the remaining 75% of the shares vest in equal monthly installments over the following 36 months, so that all of the shares become fully vested on the fourth anniversary of the grant date of February 16, 2011.
- 8. The stock option is exercisable as it vests 25% of the shares subject to the stock option vest on the first anniversary of the grant date, while the remaining 75% of the shares vest in equal monthly installments over the following 36 months, so that all of the shares become fully vested on the fourth anniversary of the grant date of February 15, 2012.

#### Remarks:

/s/ Stephen L. Cartt

08/18/2014

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.